Sentence: To review the clinical effectiveness and cost-effectiveness evidence base for lapatinib ( LAP ) in combination with an aromatase inhibitor ( AI ) and trastuzumab ( TRA ) in combination with an AI for the first-line treatment of patients who have hormone receptor-positive (HR+)/human epidermal growth factor 2-positive ( HER2 + ) mBC .
Drug combination annotation:
[{'class': 'POS', 'spans': ['lapatinib', 'AI'], 'is_context_needed': True}, {'class': 'POS', 'spans': [1, 2], 'is_context_needed': True}]